Scientific Articles

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

 

Prof Janet E Brown, MD FRCP; Kara-Louise Royle, MSc; Prof Walter Gregory, PhD; Christy Ralph, PhD; Prof Anthony Maraveyas, PhD; Omar Din, MD; Prof Timothy Eisen, MBBChir;
Prof Paul Nathan, FRCP; Prof Tom Powles, MD; Richard Griffiths, FRCP; Prof Robert Jones, PhD; Naveen Vasudev, PhD MBChB; Matthew Wheater, FRCP PhD; Abdel Hamid, FRCR MSc;
Tom Waddell, MD; Rhona McMenemin, MSc FRCR; Prof Poulam Patel, PhD; Prof James Larkin, FRCP PhD; Guy Faust, MD; Adam Martin, PhD; Jayne Swain, PhD; Janine Bestall, PhD;
Prof Christopher McCabe, PhD; David Meads, PhD; Prof Vicky Goh, MD FRCR; Prof Tze Min Wah, PhD; Prof Julia Brown, MSc; Prof Jenny Hewison, PhD; Prof Peter Selby, DSc;
Fiona Collinson, MD; on behalf of theSTAR Investigators

The Lancet Oncology, march 2023

Abstract link